– USA, CA – Better Therapeutics, Inc., a prescription digital therapeutics company delivering cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced the appointment of Dr. Risa Lavizzo-Mourey to its board of directors as Compensation Committee chair.
“Dr. Lavizzo-Mourey brings critical insights into health policy, as well as her background as a primary care physician at a critical juncture for Better Therapeutics,” said co-founder and chairman, David Perry. “Her experience and counsel will help us establish our prescription digital therapeutics as the new standard of care for people with cardiometabolic diseases.”
About Dr. Risa Lavizzo-Mourey
Dr. Lavizzo-Mourey joins the board after previously serving in various high-level roles under three presidential administrations, including as Deputy Administrator for the Agency for Health Care Policy and Research under President George H.W. Bush’s administration, as the quality of care chair for President Bill Clinton’s panels on health care, and on President Obama’s Council on Fitness, Sports and Nutrition. Her career combines geriatric medicine and health policy, focusing on disease, disability, prevention, and healthcare issues among minorities. She brings hands-on experience in the fields of research and academia, as a primary care provider, and health policy on a national level with an acute understanding of minority suffering and disenfranchisement.
“I welcome this opportunity to extend my expertise and contribute to the success of Better Therapeutics, which I believe has the potential to truly be transformative in treating cardiometabolic diseases,” said Dr. Lavizzo-Mourey.
Dr. Lavizzo-Mourey currently serves as an independent director and Nominating & Governance Committee member for Intel (NYSE: INTC), an independent director and Compensation & Benefits Committee member for Merck (NYSE: MRK), and as an independent director and Governance & Public Affairs committee member for General Electric (NYSE: GE).
Risa is the recipient of numerous awards, including twenty honorary doctorates. She has appeared on Forbes’ list of the most important women in the world eight times and as one of Modern Healthcare’s one hundred most influential people in health care eleven times.
“Prescription digital therapeutics is a rapidly evolving sector of the life science industry, and Better Therapeutics’ digitally-delivered cognitive behavioral therapy that addresses the root causes of disease has the potential to become standard practice in cardiometabolic disease treatment,” added Dr. Lavizzo-Mourey.
About Better Therapeutics
Better Therapeutics has created a platform for the development of prescription digital therapeutics (PDT) for the treatment of diabetes, heart disease, and other cardiometabolic conditions. The Better Therapeutics platform blends clinical, behavioral, and psychological inputs into a series of therapy lessons and skill-building modules designed to isolate and shift the underlying thoughts and beliefs which guide diet and lifestyle behaviors that are the root causes of a wide range of cardiometabolic diseases. The delivery of behavioral therapy enables changes in neural pathways of the brain and leads to behavioral change. These therapies and the resulting changes hold the potential to lower healthcare costs to treat these conditions and improve patient health.
Better Therapeutics’ first PDT (BT-001) is being evaluated in a pivotal trial as a treatment for type 2 diabetes used under physician supervision. It is anticipated that following marketing authorization, primary care providers will prescribe, and insurers will reimburse Better Therapeutics’ PDTs much like they would a traditional medication.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.